Printer Friendly

Synlogic receives orphan drug designation for SYNB1618.

Synlogic announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to SYNB1618, Synlogic's preclinical-stage drug candidate for the treatment of phenylketonuria , an inborn error of metabolism caused by a mutation in the gene that breaks down the amino acid phenylalanine. Phe accumulation in the blood and brain can lead to neurocognitive abnormalities and treatment currently requires severe dietary protein restriction. SYNB1618, an orally administered medicine, is designed to complement the missing function in patients with PKU by providing alternative metabolic pathways to consume Phe. Synlogic plans to file an investigational new drug application with the FDA for SYNB1618 for the potential treatment of PKU in early 2018.

COPYRIGHT 2017 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Oct 24, 2017
Words:112
Previous Article:Helios and Matheson: MoviePass surpasses over 600K paying monthly subscribers.
Next Article:Nielsen expands multi-year agreement with Sargento Foods.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters